Scholar Rock Holding annual cash and equivalents
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding Cash & Equivalents Growth & History (SRRK)
Scholar Rock Holding's cash and equivalents was $323.5M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $323.5M | $145.6M | +81.88% |
| 2024 | 2024-12-31 | $177.9M | $76.0M | +74.64% |
| 2023 | 2023-12-31 | $101.9M | −$1.4M | −1.37% |
| 2022 | 2022-12-31 | $103.3M | −$109.6M | −51.48% |
| 2021 | 2021-12-31 | $212.8M | $52.5M | +32.72% |
| 2020 | 2020-12-31 | $160.4M | $124.0M | +341.66% |
| 2019 | 2019-12-31 | $36.3M | −$78.8M | −68.45% |
| 2018 | 2018-12-31 | $115.1M | $58.6M | +103.80% |
| 2017 | 2017-12-31 | $56.5M | — | — |
Scholar Rock Holding quarterly cash and equivalents
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $437.1M | $284.2M | +185.82% |
| Q1 2026 | 2026-03-31 | $430.5M | $292.6M | +212.16% |
| Q4 2025 | 2025-12-31 | $323.5M | $145.6M | +81.88% |
| Q3 2025 | 2025-09-30 | $286.8M | $210.4M | +275.40% |
| Q2 2025 | 2025-06-30 | $152.9M | $59.6M | +63.78% |
| Q1 2025 | 2025-03-31 | $137.9M | $45.9M | +49.95% |
| Q4 2024 | 2024-12-31 | $177.9M | $76.0M | +74.64% |
| Q3 2024 | 2024-09-30 | $76.4M | $8.8M | +13.01% |
| Q2 2024 | 2024-06-30 | $93.4M | −$14.7M | −13.60% |
| Q1 2024 | 2024-03-31 | $92.0M | −$59.3M | −39.20% |
| Q4 2023 | 2023-12-31 | $101.9M | −$1.4M | −1.37% |
| Q3 2023 | 2023-09-30 | $67.6M | −$65.5M | −49.20% |
| Q2 2023 | 2023-06-30 | $108.1M | −$197.7M | −64.65% |
| Q1 2023 | 2023-03-31 | $151.3M | $51.1M | +51.02% |
| Q4 2022 | 2022-12-31 | $103.3M | −$109.6M | −51.48% |
| Q3 2022 | 2022-09-30 | $133.1M | −$43.1M | −24.45% |
| Q2 2022 | 2022-06-30 | $305.7M | $98.8M | +47.75% |
| Q1 2022 | 2022-03-31 | $100.2M | −$58.9M | −37.04% |
| Q4 2021 | 2021-12-31 | $212.8M | $52.5M | +32.72% |
| Q3 2021 | 2021-09-30 | $176.1M | $119.9M | +213.25% |
| Q2 2021 | 2021-06-30 | $206.9M | $91.8M | +79.73% |
| Q1 2021 | 2021-03-31 | $159.1M | $63.7M | +66.72% |
| Q4 2020 | 2020-12-31 | $160.4M | $124.0M | +341.66% |
| Q3 2020 | 2020-09-30 | $56.2M | $23.6M | +72.26% |
| Q2 2020 | 2020-06-30 | $115.1M | $1.3M | +1.17% |
| Q1 2020 | 2020-03-31 | $95.4M | $28.4M | +42.43% |
| Q4 2019 | 2019-12-31 | $36.3M | −$78.8M | −68.45% |
| Q3 2019 | 2019-09-30 | $32.6M | −$71.3M | −68.61% |
| Q2 2019 | 2019-06-30 | $113.8M | −$1.3M | −1.10% |
| Q1 2019 | 2019-03-31 | $67.0M | — | — |
| Q4 2018 | 2018-12-31 | $115.1M | $58.6M | +103.80% |
| Q3 2018 | 2018-09-30 | $104.0M | — | — |
| Q2 2018 | 2018-06-30 | $115.1M | — | — |
| Q4 2017 | 2017-12-31 | $56.5M | — | — |
Scholar Rock Holding cash and equivalents trends
Over the last five fiscal years, Scholar Rock Holding's cash and equivalents increased from $160.4M to $323.5M, a change of $163.2M. The latest reported quarter, Q2 2026, shows $437.1M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...